NeuroVive Pharmaceutical AB: Merger Between Oncore And Tekmira Includes Development Of NVP018 For The Treatment Of Hepatitis B
STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Neurovive Pharmaceutical(STO:NVP)
US biotechnology company OnCore Biopharma, Inc. (OnCore), which has licensed NeuroVive’s drug candidate NVP018 for the treatment of chronic Hepatitis B virus infection (HBV), has agreed to merge with Canadian listed RNAi therapeutics company Tekmira Pharmaceuticals Corporation (Tekmira). OnCore would continue as a subsidiary of Tekmira, and the licensing agreement for NVP018 between NeuroVive and OnCore will remain in force following the merger as the combined company continues to work in the HBV area.
Help employers find you! Check out all the jobs and post your resume.
Neurovive Pharmaceutical(STO:NVP)
US biotechnology company OnCore Biopharma, Inc. (OnCore), which has licensed NeuroVive’s drug candidate NVP018 for the treatment of chronic Hepatitis B virus infection (HBV), has agreed to merge with Canadian listed RNAi therapeutics company Tekmira Pharmaceuticals Corporation (Tekmira). OnCore would continue as a subsidiary of Tekmira, and the licensing agreement for NVP018 between NeuroVive and OnCore will remain in force following the merger as the combined company continues to work in the HBV area.
Help employers find you! Check out all the jobs and post your resume.